Allergan Unlimited Company, formerly Allergan Limited, is an Ireland-based pharmaceutical company. The Company is focused on developing, manufacturing and commercializing branded pharmaceutical, device, biologic, surgical and regenerative medicine products for patients around the world. The Company's products primarily focus on four key therapeutic areas, including medical aesthetics, eye care, central nervous system and gastroenterology.

Employees

Sector

Pharmaceuticals

More about the company

Delayed NYSE Other stock markets			5-day change	1st Jan Change
- ^USD	-.--%		+1.73%	+0.97%

Apr. 07	Allergan Aesthetics Opens New Ami Training Center in Austin	CI
Mar. 31	Allergan Aesthetics Announces Fourth Annual CoolMonth With Deals On CoolSculpting	CI

Market Cap	63.66B 55.82B 51.45B 48.17B 90.32B 6,005B 92.2B 618B 239B 2,968B 239B 234B 10,291B	P/E 2018	-8.76x	P/E 2019	-11.9x
Enterprise Value	80.96B 70.99B 65.44B 61.26B 115B 7,638B 117B 786B 304B 3,775B 304B 297B 13,089B	EV / Sales 2018	4.24x	EV / Sales 2019	4.98x
Free-Float	99.9%	Yield 2018	2.15%	Yield 2019	1.55%

Apr. 07	Allergan Aesthetics Opens New Ami Training Center in Austin	CI
Mar. 31	Allergan Aesthetics Announces Fourth Annual CoolMonth With Deals On CoolSculpting	CI
Mar. 30	Allergan Aesthetics Presents Findings on Safety and Efficacy of Repeat Trenibote Treatments and Data on Medical Weight Loss Aesthetics Patient Behaviors At the 2026 American Academy of Dermatology Meeting	CI
Mar. 19	Allergan Aesthetics Reveals Evolution in Approach to Modern Aesthetic Treatments with Comprehensive Global Survey and New Educational Solutions	CI
Mar. 04	Allergan Aesthetics Shares Medical Weight Loss Data and the Changing Profile of Patients	CI
Nov. 12	Allergan Aesthetics Unveils New Data at 2025 American Society for Dermatologic Surgery Annual Meeting Showcasing Transformative Innovation and Portfolio Excellence	CI
25-09-25	AllAllergan Aesthetics to Showcase Multimodal Treatment Approach and Continued Commitment to Skin Quality At AMWC Dubai	CI
25-08-19	Allergan Aesthetics Unveils Its Newest Hydration Hero	CI
25-06-30	U.S. Food and Drug Administration Accepts for Review Allergan Aesthetics Premarket Approval Application for Skinvive by Juvederm for the Improvement of Neck Appearance	CI
25-02-12	Allergan Aesthetics to Launch Three New Training Centers in the U.S. Expanding Access to High Quality Aesthetics Training	CI
24-10-18	BOTOX® Cosmetic (onabotulinumtoxinA) Receives FDA Approval for Moderate to Severe Vertical Bands Connecting the Jaw and Neck (Platysma Bands)	CI
24-08-27	Allergan Aesthetics Announces the Launch of Its Next Generation Hydration Product: Skinmedica HA5 Hydra Collagen Replenish + Restore Hydrator	CI
24-06-27	Allergan Aesthetics Debuts Alle Payment Plans	CI

24-04-01	Court Dismisses Class Action Against Biopharmaceutical Company For Failing To Disclose Progress Of Competitor; Second Circuit Affirms Dismissal Of Putative Class Action Against Allergan; Eleventh Circuit Affirms That "Toxic" Lender Qualified As A "Dealer" Under The Exchange Act Due To High-Volume Trading; Delaware Court Of Chancery Invalidates Governance Rights In Stockholder Agreement	AQ
22-04-20	Allergan, an AbbVie Company, to Present New Data from its Eye Care Portfolio at the 2022 American Society of Cataract and Refractive Surgery (ASCRS) Annual Meeting	AQ
22-04-06	Allergan, an AbbVie Company, Announces Positive Topline Phase 3 Results Evaluating Investigational Twice-Daily Administration of VUITY 1.25% in Adults with Age-Related Blurry Near Vision	AQ
22-03-22	AbbVie and Allergan Aesthetics to Present New Research Across Dermatology Portfolio at 2022 AAD Annual Meeting	AQ
21-12-10	Allergan - VUITY 1.25%, the First and Only FDA-Approved Eye Drop to Treat Age-Related Blurry near Vision, is Now Available	AQ

Allergan plc Stock

Stocks

AGN

IE00BY9D5467

Pharmaceuticals

Valuation: Allergan plc

Latest news : Allergan plc

Press Releases: Allergan plc

News in other languages: Allergan plc

Managers and Directors: Allergan plc

Latest insider transactions

Other Pharmaceuticals

Financials

Company Profile

21-04-20	Planète Bourse : La revue de presse du mardi 20 avril 2021
20-05-07	EN DIRECT DES MARCHES : Air France KLM, ArcelorMittal, Legrand, Natixis, Peugeot, Eurofins, Zalando, Facebook...
20-05-07	La Chine repart, mais Washington veille
20-05-06	EN DIRECT DES MARCHES : Danone, Sanofi, Crédit Agricole, Arkema, Neoen, Eurofins, BMW, Novo Nordisk...
20-05-06	Trump franchit le Rubicon

Manager	Title	Age	Since
Alex Thurman DFI	Director of Finance/CFO	56	2016-11-30
Robert Michael PSD	President	55	2020-05-07

Director	Title	Age	Since
Robert Michael BRD	Director/Board Member	55	2020-05-07
Scott Reents BRD	Director/Board Member	-	2020-05-07
Ryan Quigley BRD	Director/Board Member	-	2020-05-07

Date	Insider	Type	Main position	Quantity	% Market Cap.
20-05-07	Matthew Walsh	Issuer sale	Chief Financial Officer	67,678	0.0206%
20-05-07	Brenton Saunders	Issuer sale	Chief Executive Officer	720,227	0.2189%
20-05-07	Nesli Basgoz	Issuer sale	Director	15,989	0.0049%

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
ALLERGAN PLC	-.--%	+1.73%	-	-	63.66B
ELI LILLY AND COMPANY	+7.13%	+9.97%	+55.80%	+163.38%	1,077B
JOHNSON & JOHNSON	+3.99%	+11.50%	+67.09%	+56.27%	613B
ABBVIE INC.	+4.20%	+17.03%	+38.97%	+91.19%	448B
ROCHE HOLDING AG	+0.99%	+4.85%	+28.17%	+22.04%	332B
ASTRAZENECA PLC	+1.82%	+8.19%	+40.04%	+27.45%	293B
NOVARTIS AG	+0.22%	+6.75%	+31.30%	+42.64%	286B
NOVO NORDISK A/S	+0.73%	+8.53%	-27.33%	-40.29%	215B
AMGEN INC.	+1.56%	+6.14%	+29.30%	+61.91%	193B
GILEAD SCIENCES, INC.	+3.26%	+3.33%	+15.55%	+67.87%	159B
Average	+2.39%	+7.80%	+30.99%	+54.72%	367.97B
Weighted average by Cap.	+3.78%	+9.52%	+41.75%	+81.02%

	2018	2019
Net sales	15.79B 13.84B 12.76B 11.95B 22.4B 1,489B 22.86B 153B 59.34B 736B 59.28B 57.99B 2,552B	16.09B 14.11B 13B 12.17B 22.83B 1,518B 23.3B 156B 60.47B 750B 60.41B 59.09B 2,601B
Net income	-5.1B -4.47B -4.12B -3.86B -7.23B -481B -7.38B -49.51B -19.16B -238B -19.14B -18.72B -824B	-5.27B -4.62B -4.26B -3.99B -7.48B -497B -7.63B -51.2B -19.81B -246B -19.79B -19.36B -852B
Net Debt	21.89B 19.19B 17.69B 16.56B 31.06B 2,065B 31.7B 213B 82.28B 1,021B 82.2B 80.4B 3,539B	17.3B 15.17B 13.99B 13.09B 24.55B 1,632B 25.06B 168B 65.04B 807B 64.98B 63.56B 2,797B